Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Reversing radiation-activated immune suppression in cancer (opens in a new tab)

medicalxpress.com · 2026-10-31

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

2 claims go further than the study. 3 other points were not covered by the paper.

  • 1 supported
  • 2 overstated
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

Two of six claims overstate the study. One of six checks out. Three claims the study doesn't address.

  • 1 supported
  • 2 overstated
  • 3 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedResearchers at the University of Chicago have identified a mechanism to make immune cells reprogrammed by radiation therapy attack tumors rather than protect them.View evidenceHide evidence

Why this verdict

The abstract supports a causal preclinical mechanism: Tet2 loss or inhibition can redirect myeloid differentiation toward antigen-presenting/activating cells and improve antitumor responses after radiotherapy. However, the headline is unqualified and makes the mechanism sound generally established as a way to make radiation-reprogrammed immune cells attack tumors, whereas the therapeutic evidence is primarily mouse/preclinical and abstract-level.

1

Study evidence

Myeloid-specific Tet2 deletion following radiotherapy suppresses tumor progression and redirects monocyte differentiation toward antigen-presenting MDACs.

“Following radiotherapy, myeloid-specific Tet2 deletion suppresses tumor progression and redirects monocyte differentiation toward antigen-presenting myeloid-derived activating cells (MDACs), which augment antitumor T cell responses”
2

Study evidence

Pharmacologic TET2 inhibition recapitulated the Tet2 genetic-loss phenotype of redirecting myeloid differentiation toward antigen-presenting myeloid-derived activating cells (MDACs) and augmenting antitumor T cell responses (abstract).

“Pharmacological TET2 inhibition recapitulates this phenotype and augments radiotherapy and PD-L1 blockade to control primary and metastatic tumors.”
Claim 2 of 6OverstatedWhen the researchers blocked TET2, the same cells began fighting cancer instead, helping radiation and immunotherapy shrink tumors and control metastasis.View evidenceHide evidence

Why this verdict

The abstract supports that Tet2 loss and pharmacologic TET2 inhibition reprogram myeloid differentiation, augment antitumor T cell responses, and improve control of primary and metastatic tumors with radiotherapy/checkpoint blockade in mouse models. But the lead does not clearly confine this to preclinical models, and 'shrink tumors' is stronger/more specific than the abstract's wording of suppressing progression or controlling tumors.

1

Study evidence

Myeloid-specific Tet2 deletion following radiotherapy suppresses tumor progression and redirects monocyte differentiation toward antigen-presenting MDACs.

“Following radiotherapy, myeloid-specific Tet2 deletion suppresses tumor progression and redirects monocyte differentiation toward antigen-presenting myeloid-derived activating cells (MDACs), which augment antitumor T cell responses”
2

Study evidence

Pharmacologic TET2 inhibition recapitulated the Tet2 genetic-loss phenotype of redirecting myeloid differentiation toward antigen-presenting myeloid-derived activating cells (MDACs) and augmenting antitumor T cell responses (abstract).

“Pharmacological TET2 inhibition recapitulates this phenotype and augments radiotherapy and PD-L1 blockade to control primary and metastatic tumors.”
Claim 3 of 6Not coveredThe team analyzed blood samples collected before and after treatment from 33 patients with stage IV non-small cell lung cancer enrolled in a clinical trial combining high-dose, precisely targeted radiation with nivolumab and ipilimumab.View evidenceHide evidence

As stated33 patients

Why this verdict

The abstract-level profile supports a human observational association in advanced lung cancer patients receiving radio-immunotherapy, but it does not provide the claimed sample size of 33, stage IV status, before/after blood-sample timing, high-dose targeted radiation details, or the specific use of nivolumab and ipilimumab.

1

Study evidence

TET2 expression correlates with poor clinical outcomes in advanced lung cancer patients receiving radiotherapy plus immunotherapy.

“We identify TET2 as a radiation-induced regulator of myeloid-derived suppressor cells whose expression correlates with poor outcomes in advanced lung cancer patients receiving radio-immunotherapy.”
Claim 4 of 6Not coveredIn mouse models of colon cancer, melanoma and lung cancer, mice lacking TET2 only in myeloid cells showed slower tumor growth after radiation, longer survival and fewer, smaller lung metastases than normal mice.View evidenceHide evidence

Why this verdict

The abstract supports the general finding that myeloid-specific Tet2 deletion after radiotherapy suppresses tumor progression and metastasis in mouse tumor models. However, the abstract profile does not verify the specific cancer models listed, longer survival, or the description of fewer and smaller lung metastases.

1

Study evidence

Myeloid-specific Tet2 deletion following radiotherapy suppresses tumor progression and redirects monocyte differentiation toward antigen-presenting MDACs.

“Following radiotherapy, myeloid-specific Tet2 deletion suppresses tumor progression and redirects monocyte differentiation toward antigen-presenting myeloid-derived activating cells (MDACs), which augment antitumor T cell responses”
Claim 5 of 6Not coveredThe article says an experimental TET2-blocking drug led to slow tumor growth, fewer and smaller lung metastases when combined with radiation, and an improved response to immunotherapy.View evidenceHide evidence

Why this verdict

The abstract supports that pharmacologic TET2 inhibition recapitulates the Tet2-loss phenotype and, with radiotherapy plus PD-L1 blockade, improves control of primary and metastatic tumors in mice. At abstract depth, it does not verify the drug identity, exact tumor-growth metric, or the specific claim of fewer and smaller lung metastases.

1

Study evidence

Pharmacologic TET2 inhibition recapitulated the Tet2 genetic-loss phenotype of redirecting myeloid differentiation toward antigen-presenting myeloid-derived activating cells (MDACs) and augmenting antitumor T cell responses (abstract).

“Pharmacological TET2 inhibition recapitulates this phenotype and augments radiotherapy and PD-L1 blockade to control primary and metastatic tumors.”
Claim 6 of 6SupportedThe study, published in Cancer Cell, shows that radiation activates a protein called TET2 on immune cells in bone marrow, where it removes chemical tags from RNA and locks these cells into an immune-suppressing state.View evidenceHide evidence

Why this verdict

The abstract supports that radiation induces a TET2-driven immunosuppressive myeloid program, that a fate program initiates rapidly in bone marrow, and that a p53-TET2 axis decreases m5C on chromatin-associated RNAs, promoting immunosuppressive chromatin compaction and interferon-signal silencing. The story simplifies the molecular chain, but the core mechanism is supported at abstract depth.

1

Study evidence

TET2 expression correlates with poor clinical outcomes in advanced lung cancer patients receiving radiotherapy plus immunotherapy.

“We identify TET2 as a radiation-induced regulator of myeloid-derived suppressor cells whose expression correlates with poor outcomes in advanced lung cancer patients receiving radio-immunotherapy.”
2

Study evidence

Spatiotemporal mapping shows the MDAC fate program initiates rapidly in the bone marrow after radiotherapy.

“spatiotemporal mapping shows that this fate program initiates rapidly in the bone marrow.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The human clinical component is observational and correlational; the abstract does not establish that TET2 causes poorer patient outcomes, and it provides no effect estimates or confounding analysis.

    The story uses some associational language such as 'linked,' but its caveats do not clearly state that the human evidence is observational, potentially confounded, and non-causal.

    From observational cohort study (human)

  • Mechanism: a radiation-responsive p53-TET2 axis decreases m5C on chromatin-associated RNAs, driving immunosuppressive chromatin compaction and interferon-signal silencing; Tet2 loss restores chromatin accessibility and enhances CD8+ T cell cytotoxicity.

    The story captures the simplified idea that TET2 removes RNA chemical tags and promotes an immunosuppressive state, but it omits key mechanistic components emphasized in the abstract: p53, chromatin-associated RNAs, chromatin compaction/accessibility, interferon signaling, and CD8+ T cell cytotoxicity.

    From other

5 things the story did carry across
  • Radiation induces a TET2-driven immunosuppressive myeloid/MDSC program associated with poor outcomes in advanced lung cancer patients receiving radio-immunotherapy.
  • In mouse radiotherapy models, myeloid-specific Tet2 loss redirects monocyte differentiation toward antigen-presenting MDACs, augments antitumor T cell responses, and suppresses primary tumor progression and metastasis.
  • Pharmacologic TET2 inhibition recapitulates the Tet2-loss phenotype and, combined with radiotherapy and PD-L1 blockade, improves control of primary and metastatic tumors in mouse models.
  • Spatiotemporal mapping shows the myeloid fate program initiates rapidly in the bone marrow after radiotherapy.
  • The therapeutic efficacy evidence is preclinical; translation to improved patient outcomes is suggested but not demonstrated by the abstract.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

5

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalIn vivo, myeloid-specific Tet2 loss (and pharmacologic TET2 inhibition) reprograms myeloid differentiation toward antigen-presenting MDACs, improving radiotherapy responses and suppressing metastasis; combination with PD-L1 blockade is beneficial.In vivo mouse radiotherapy with myeloid-specific Tet2 deletionExpand

In plain English

In mouse tumor radiotherapy models, myeloid-lineage deletion of Tet2 after radiotherapy redirects monocyte differentiation toward antigen-presenting myeloid-derived activating cells (MDACs), suppresses primary tumor progression and metastasis, and augments antitumor T cell responses; pharmacologic TET2 inhibition phenocopies these effects and improves outcomes when combined with radiotherapy and PD-L1 blockade.

Key findings

  • Myeloid-specific Tet2 deletion following radiotherapy suppresses tumor progression and redirects monocyte differentiation toward antigen-presenting MDACs.
  • Tet2 loss promotes generation of MDACs that augment antitumor T cell responses and is associated with enhanced CD8+ T cell cytotoxicity.
“Following radiotherapy, myeloid-specific Tet2 deletion suppresses tumor progression and redirects monocyte differentiation toward antigen-presenting myeloid-derived activating cells (MDACs), which augment antitumor T cell responses”
What this piece can’t prove

3 further details could not be confirmed from the summary.

2human in vivoRadiation induces a TET2-driven immunosuppressive myeloid program (MDSC) associated with poor outcomes in lung cancer patients receiving radio-immunotherapy.observational cohort study (human)Expand

In plain English

The abstract reports an observational association from advanced lung cancer patients treated with radiotherapy plus immunotherapy: TET2 is identified as a radiation-induced regulator of myeloid-derived suppressor cells, and higher TET2 expression correlates with poorer clinical outcomes in this patient group. Specific cohort, assay, and statistical details are not provided in the abstract.

Key findings

  • TET2 expression correlates with poor clinical outcomes in advanced lung cancer patients receiving radiotherapy plus immunotherapy.
“We identify TET2 as a radiation-induced regulator of myeloid-derived suppressor cells whose expression correlates with poor outcomes in advanced lung cancer patients receiving radio-immunotherapy.”
What this piece can’t prove
  • No information on the assay platform, normalization, or compartment (tumor vs. blood vs. sorted myeloid cells) used to measure TET2 expression.
  • Observational association may be subject to confounding and reverse causation; causality is not established from the reported correlation.

2 further details could not be confirmed from the summary.

3in vivo animalIn vivo, myeloid-specific Tet2 loss (and pharmacologic TET2 inhibition) reprograms myeloid differentiation toward antigen-presenting MDACs, improving radiotherapy responses and suppressing metastasis; combination with PD-L1 blockade is beneficial.in vivo pharmacologic combinationExpand

In plain English

In mouse tumor models, pharmacologic inhibition of TET2 recapitulated the myeloid reprogramming observed with myeloid-specific Tet2 loss (generation of antigen-presenting MDACs and augmented antitumor T cell responses) and, when combined with radiotherapy and anti–PD-L1 checkpoint blockade, improved control of primary tumors and suppressed metastatic disease (abstract-reported).

Key findings

  • Pharmacologic TET2 inhibition recapitulated the Tet2 genetic-loss phenotype of redirecting myeloid differentiation toward antigen-presenting myeloid-derived activating cells (MDACs) and augmenting antitumor T cell responses (abstract).
  • Pharmacologic TET2 inhibition, when combined with radiotherapy and anti–PD-L1 blockade, improved control of primary tumors and suppressed metastasis in mouse models (abstract).
“Pharmacological TET2 inhibition recapitulates this phenotype and augments radiotherapy and PD-L1 blockade to control primary and metastatic tumors.”
What this piece can’t prove

2 further details could not be confirmed from the summary.

4in vivo animalSpatiotemporal mapping shows MDAC fate programming initiates rapidly in the bone marrow after radiotherapy.in vivo time-course spatiotemporal mappingExpand

In plain English

The paper reports spatiotemporal mapping of myeloid fate after radiotherapy and states that the MDAC (myeloid-derived activating cell) fate program is initiated rapidly in the bone marrow following treatment. This mapping is presented as temporal and anatomical evidence locating the early initiation of the MDAC differentiation trajectory to the bone marrow compartment.

Key findings

  • Spatiotemporal mapping shows the MDAC fate program initiates rapidly in the bone marrow after radiotherapy.
“spatiotemporal mapping shows that this fate program initiates rapidly in the bone marrow.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

5otherMechanism: a radiation-responsive p53–TET2 axis reduces m5C on chromatin-associated RNAs, promoting immunosuppressive chromatin compaction and interferon-signal silencing; Tet2 loss restores accessibility and enhances CD8+ T cell cytotoxicity.Expand

In plain English

Abstract-level mechanistic claim: following radiotherapy a radiation-responsive p53–TET2 axis reduces 5-methylcytosine (m5C) on chromatin-associated RNAs (caRNAs), which is reported to promote immunosuppressive chromatin compaction and silencing of interferon signaling; loss or inhibition of Tet2 is reported to restore chromatin accessibility and enhance CD8+ T cell cytotoxicity.

Key findings

  • A radiation-responsive p53–TET2 axis decreases m5C on chromatin-associated RNAs, which is reported to drive immunosuppressive chromatin compaction and silencing of interferon signaling; Tet2 loss restores chromatin accessibility and enhances CD8+ T cell cytotoxicity.
“Mechanistically, a radiation-responsive p53-TET2 axis decreases m5C on chromatin-associated RNAs (caRNAs), enforcing immunosuppressive chromatin compaction and silencing interferon signaling, whereas Tet2 loss restores chromatin accessibility and enhances CD8+ T cell cytotoxicity.”
What this piece can’t prove
  • Abstract does not specify the exact assays or experimental models used to measure caRNA m5C, chromatin compaction/accessibility, interferon signaling, or CD8+ T cell cytotoxicity.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 37 candidate papers

Candidate

Author response for "Synergistic remediation of aqueous Cd(II) by sewage sludge biochar via P/Fe co-impregnation"

2026 · Crossref

Source (opens in a new tab)

And 31 more candidates considered.